

# Cloning and sequencing of *cagA* gene fragment of *Helicobacter pylori* with coccoid form

Ke-Xia Wang, Xue-Feng Wang

**Ke-Xia Wang, Xue-Feng Wang**, School of Medicine, Anhui University of Science & Technology Huainan 232001, Anhui Province, China  
**Supported by** Natural Science Foundation of the Education Department of Anhui Province, China No.2003kj111

**Correspondence to:** Dr. Ke-Xia Wang, Department of Etiology and Immunology, School of Medicine, Anhui University of Science & Technology, Huainan 232001, Anhui Province, China. kexiawang2003@yahoo.com.cn

**Telephone:** +86-554-6658770 **Fax:** +86-554-6662469

**Received:** 2003-10-20 **Accepted:** 2003-12-08

## Abstract

**AIM:** To clone and sequence the *cagA* gene fragment of *Helicobacter pylori* (*H pylori*) with coccoid form.

**METHODS:** *H pylori* strain NCTC11637 were transformed to coccoid form by exposure to antibiotics in subinhibitory concentrations. The coccoid *H pylori* was collected. *cagA* gene of the coccoid *H pylori* strain was amplified by PCR. After purified, the target fragment was cloned into plasmid pMD-18T. The recombinant plasmid pMD-18T-*cagA* was transformed into *E.coli* JM109. Positive clones were screened and identified by PCR and digestion with restriction endonucleases. The sequence of inserted fragment was then analysed.

**RESULTS:** *cagA* gene of 3 444 bp was obtained from the coccoid *H pylori* genome DNA. The recombinant plasmid pMD-18T-*cagA* was constructed, then it was digested by *Bam*H I + *Sac* I, and the product of digestion was identical with the predicted one. Sequence analysis showed that the homology of coccoid and the reported original sequence *H pylori* was 99.7%.

**CONCLUSION:** The recombinant plasmid containing *cagA* gene from coccoid *H pylori* has been constructed successfully. The coccoid *H pylori* contain completed *cagA* gene, which may be related to pathogenicity of them.

Wang KX, Wang XF. Cloning and sequencing of *cagA* gene fragment of *Helicobacter pylori* with coccoid form. *World J Gastroenterol* 2004; 10(23): 3511-3513  
<http://www.wjgnet.com/1007-9327/10/3511.asp>

## INTRODUCTION

*Helicobacter pylori* (*H pylori*) is one of the common bacteria causing chronic infection, which infects more than 50% of the human population, causes chronic gastritis and plays an important role in the pathogenesis of gastroduodenal ulceration. *H pylori* has also been suggested to be involved in the genesis of adenocarcinoma and MALT lymphoma of the stomach.<sup>[1-5]</sup> *H pylori* cells growing actively *in vitro* are curved rods, which evolve into metabolically active but nonculturable coccoid cells after prolonged incubation<sup>[6-8]</sup>. In the stomach mostly spiral-shaped bacteria are found, but coccoid cells have been observed

in the more severely damaged regions of the gastric mucosa<sup>[9,10]</sup>. Many scholars believed that coccoid *H pylori* might lead to difficult recovery, easy relapse and epidemical transmission<sup>[11]</sup>. But the pathogenicity of coccoid *H pylori* is unclear at present. The cytotoxin-associated protein encoded by *cagA* (cytotoxin-associated gene A) is important virulence determined by *H pylori*. *cagA*<sup>+</sup> *H pylori* strains have been linked to more severe gastric inflammation, peptic ulcer disease, and gastric cancer in adults<sup>[12-15]</sup>. *CagA* gene is a mono-replicon and locates 3' region of *cag*-PAI (*cag* pathogenity island), whose length varies from 3 400 bp to 4 000 bp. In order to probe into possible pathogenesis of coccoid *H pylori*, the recombinant plasmid encoding *cagA* gene of coccoid *H pylori* was constructed and detected for the sequence in this study.

## MATERIALS AND METHODS

### Materials

The strain NCTC11637 of *H pylori* was afforded by Chinese center for disease control and prevention. JM109 *E.coli* strains were preserved by our laboratory, pMD-18T (T-Vector), restriction endonuclease enzymes (*Bam*H I, *Sac* I), T<sub>4</sub> DNA ligase, LA Taq DNA polymerase, DNA Extraction Kit and DNA purification reagent kit were provided by TaKaRa Company.

**Bacterial culture and induction of coccoid forms** *H pylori* strains were grown on Columbia agar with 50 mL frozen-melting sheep blood, 100 mL/L fetal bovine serum, and Skirrow's antibiotic supplement in a microaerophilic atmosphere for 3 d at 37 °C, then the bacteria were suspended in brucella broth and supplemented with 0.02 mg/L of amphotericin, still were incubated at 37 °C for 3, 5, 7, and 10 d. Baterial morphology was determined by light microscopy after Gram staining. The coccoid forms were collected and stored at -20 °C.

**Extraction of genomic DNA** *H pylori* of coccoid form were added to a 1.5 mL microcentrifuge tube, rinsed once with phosphate-buffered saline (PH 7.2), and pelleted by centrifugation at 11 000 g. Genomic DNA was extracted by TaKaRa MiniBEST Bacterial Genomic DNA Extraction Kit, the DNA pellet was suspended in TE (10 mmol/L Tris-HCL, 1 mmol/L PH 8.0 EDTA), and stored at -20 °C.

**Synthetic primers** A single primer pair was used to amplify coccoid *H pylori* *cagA* gene based on GenBank. The primers had a *Bam*H I site incorporated into the 5' end and a *Sac* I site at the 3' end and their sequences as follows (5'-3'): AAGGATCC ACTAACGAAACCATTGACCA (forward) and AAGAGCTCA GATTTTTGGAAACCACCTT (reverse). The 5' region initiator and 3' end stop codon were banned.

**PCR amplification** PCR was performed in a 100 µL reaction mixture in 0.6-mL tube in an automatic thermal cycler (TP3000; TaKaRa BIO INC). The PCR mixture contained 10 µL of 10×PCR buffer, 1 µL of sample DNA, 10 µL of 2.5 mmol/L deoxynucleoside triphosphate, 4 µL of 10 µmol/L oligonucleotide primers, 0.5 µL of LA Taq polymerase, 74.5 µL of molecular-biology-grade distilled water. The mixtures were incubated for 1 min at 94 °C for initial denaturation of the target DNA and then subjected to 30 cycles of denaturation at 98 °C for 10 s, annealing at 55 °C for 30 s, and extension at 72 °C for 210 s. The amplified products (5 µL) were analyzed by electrophoresis on 10 g/L agarose gel

containing 0.1 µg of ethidium bromide per ml in TBE buffer. The PCR product was visualized under UV light and photographed. **Construction of recombinant plasmids** The PCR product was purified by TaKaRa PCR Fragment Recovery Kit. The purified product was cloned into the compatible sites of the T-vector pMD-18T by using T<sub>4</sub> DNA ligase at a molar ratio of 6:1 at 16 °C for 3 h. After the above product was transformed into *E. coli* JM109, pMD-18T/cagA was selected and identified by PCR and enzyme digestion.


**Extraction of recombinant plasmid** The single bacterial colony (JM109/pMD-18T/cagA) was picked, and cultivated in 3 mL LB broth containing 100 mg/L of ampicillin, at 300 r/min at 37 °C overnight, then recombinant plasmids were extracted according to manufacturer's instructions (TaKaRa MiniBest DNA Purification Kit), in the meantime, identified by PCR and restriction endonuclease enzyme digestion.

**Sequence determination and homology analysis** The sequence determination of cagA gene of recombinant plasmid was carried out by Takara Company, in the meantime, the sequence of gene and amino acid were analyzed by software sequence 3.0, and compared the homology based on the GenBank.

## RESULTS

### PCR amplification of coccoid *H pylori* cagA gene


*H pylori* with coccoid form cagA was amplified by PCR from the above primers and The PCR product was electrophoresed and visualized by 10 g/L agarose gel (Figure 1). It revealed that the size of cagA DNA fragment amplified by PCR was 3 444 bp, and was compatible with the expectant size.



**Figure 1** 10 g/L agarose gel electrophoresis of cagA DNA fragment amplified by PCR from coccoid *H pylori*. Lane 1. PCR products, Lane M: λ-*Hind* III DNA marker.

### Identification of recombinant vector by PCR

The plasmid was extracted from recombinant bacteria and conducted as template to amplify by PCR under the condition mentioned above. The PCR products were visualized by 10 g/L agarose gel electrophoresis (Figure 2). It indicated that recombinant plasmid contained the objective gene. At the same time, it was successful in transforming recombinant plasmid into JM109 *E. coli*.




**Figure 2** Identification of recombinant vector by PCR. Lane m: λ-*Hind* III DNA marker; Lane 1: amplification cagA gene from recombinant pMD-18T-cagA plasmid by PCR; Lane 2: Amplification cagA gene from coccoid *H pylori* genome DNA by PCR.

### pMD-18T/cagA identification by restriction enzyme digestion

Recombinant plasmid pMD-18T/cagA was digested by bi-


enzyme digestion with *Bam*H I and *Sac* I, then digestive product was visualized on 10 g/L agarose gel (Figure 3). It demonstrated that recombinant plasmid was digested to 3 444 bp and 2 692 bp DNA fragment, which contained the objective gene.



**Figure 3** The identification of the pMD-18T-cagA by digestion with restriction endonucleases Lane1: Recombinant pMD-18T-cagA digested by *Bam*H I plus *Sac* I; Lane 2: Amplification cagA gene from coccoid *H pylori* genome DNA by PCR; m: λ-*Hind* III DNA marker.

### Sequence analysis of cloned cagA gene of coccoid

*H pylori* Sequence of inserted DNA was analyzed with BcaBEST Primer M13-47/BcaBEST Primer RV-M using automatic sequence analyzer by Sanger dideoxy chain termination method. The result of analysis showed that the size of inserted DNA was about 3 444 bp and 99.7% affinity in comparison with DNA sequence published on GenBank (locus: AB015416). The sequence of partial vacA gene was showed in Figure 4.



**Figure 4** sequencing result of partial cagA gene.

## DISCUSSION

Morphological conversion from spiral *H pylori* to coccoid forms has been described under several suboptimal conditions. These conditions include aerobiosis, alkaline pH, high temperature, extended incubation, or treatment with proton pump inhibitor or antibiotics<sup>[16-18]</sup>. This coccoid form conversion phenomenon, which has been thought to result in a viable but nonculturable form of the bacterium, is not exclusive to *H pylori*, as it is common for other enteric pathogens. Controversy remains about the pathogenicity of coccoid *H pylori*. Many investigators have suggested that the coccoid form of *H pylori* represents a degenerative form with no infectious capability, but others believed that the coccoid form retains a weak metabolic activity, important structural components, and pathogenicity<sup>[19-21]</sup>. Recently, successful infection with coccoid forms of *H pylori* in animal models has been reported<sup>[22-24]</sup>. These findings have highlighted the possible role of the coccoid forms in transmission of infection and morphological conversion of coccoids to the spiral form. It is well known that cagA is an important virulence factor of *H pylori* and related to severe gastrointestinal diseases. However, the research of cagA gene of coccoid *H pylori* is few at present. In order to observe cagA and vacA expression

during conversion to the coccoid form, Sisto *et al.*<sup>[25]</sup> analyzed the expression of ureA, cagA, vacA genes after prolonged incubation in a liquid medium in 2000, the results showed that although the coccoid forms had decreased DNA and RNA levels after 31 d, they were not degraded and still expressed the urease, cytotoxic island and vacuolating toxin genes. So in conclusion, coccoid forms are therefore viable and may act as a transmissible agent that plays a crucial role in disease relapses after antibiotic therapy. She *et al.* explored the virulence and the potential pathogenicity of coccoid *H pylori* transformed from spiral form by exposure to antibiotic in 2001, and found that the content of the protein with the molecular weight over  $M_r$  74 000 decreased, but vacA, cagA, urea, ureB, hpaA gene remained to be preserved, so they concluded that the virulence and the proteins with molecular weight over  $M_r$  74 000 in coccoid *H pylori* decrease, but no deletion exists in amplification fragments from ureA, ureB, hpaA, vacA and cagA genes, and suggested that coccoid *H pylori* may have potential pathogenicity. Furthermore, Monstein *et al.*<sup>[26]</sup> confirmed that the transcription and translation of cagA and vacA gene might actively take place in coccoid *H pylori* cells.

In order to research the cagA gene existence, and explore the possible mechanism of pathogenicity in coccoid *H pylori*, we designed the specific primers based on cagA gene sequence reported in GenBank, and successfully amplified the cagA gene of coccoid *H pylori* by PCR, then inserted into pMD-18T vector. The recombinant plasmids were successfully identified containing cagA gene fragment by PCR and enzyme digestion, and sequence determination confirmed that cagA gene existed in coccoid *H pylori*, though existence of 0.3% difference with the reported sequence in GenBank. The reason for the discrepancy might be as follows: (1) the mutant base could come from the process of PCR amplification and sequencing, (2) *H pylori* provided have the transformation ability, which could lead to *H pylori* variation and genome reset. Our results also support the assumption that virulence-gene expression is differently regulated among *H pylori* strains.<sup>[26]</sup>

In this study, the NCTC11637 strain with amphotericin for 3 d generated a high proportion of coccoid forms. Forms obtained after removal of bacterial clumps and amorphous debris by centrifugation at 600 r/min for 5 min were nearly 100% coccoid. Due to similar to the condition *in vivo* by antibiotic induction, the collected coccoid *H pylori* still remained complete cellular structure, and their genome DNA lost was less, so some important virulent gene, such as vacA, cagA and so on, could exist in their cells. Once coccoid *H pylori* live in suitable condition, they can recover their virulence and lead to the occurrence of diseases. Or coccoid *H pylori* may revert helical form, and result in the transmission and/or relapse of diseases with the complete cagA gene.

## REFERENCES

- 1 Nguyen TN, Barkun AN, Fallone CA. Host determinants of *Helicobacter pylori* infection and its clinical outcome. *Helicobacter* 1999; **4**: 185-197
- 2 Vandenplas Y. *Helicobacter pylori* infection. *World J Gastroenterol* 2000; **6**: 20-31
- 3 Sakai T, Ogura Y, Narita J, Suto T, Kimura D, Aina S, Fujita H, Kamada M. Simultaneous early adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach associated with *Helicobacter pylori* infection. *Gastric Cancer* 2003; **6**: 191-196
- 4 Satoh K, Sugano K. Causal relationship between *Helicobacter pylori* infection and upper gastroduodenal diseases. *Nippon Rinsho* 2001; **59**: 239-245
- 5 Muller S, Seifert E, Stolte M. Simultaneous MALT-type lymphoma and early adenocarcinoma of the stomach associated with *Helicobacter pylori* gastritis. *Z Gastroenterol* 1999; **37**: 153-157
- 6 Ren Z, Pang G, Musicka M, Dunkley M, Batey R, Beagley K, Clancy R. Coccoid forms of *Helicobacter pylori* can be viable. *Microbios* 1999; **97**: 153-163
- 7 Willen R, Carlen B, Wang X, Papadogiannakis N, Odselius R, Wadstrom T. Morphologic conversion of *Helicobacter pylori* from spiral to coccoid form. Scanning (SEM) and transmission electron microscopy (TEM) suggest viability. *Ups J Med Sci* 2000; **105**: 31-40
- 8 Mizoguchi H, Fujioka T, Nasu M. Evidence for viability of coccoid forms of *Helicobacter pylori*. *J Gastroenterol* 1999; **11**(Suppl 11): 32-36
- 9 Saito N, Konishi K, Sato F, Kato M, Takeda H, Sugiyama T, Asaka M. Plural transformation-processes from spiral to coccoid *Helicobacter pylori* and its viability. *J Infect* 2003; **46**: 49-55
- 10 Janas B, Czkwianianc E, Bak-Romaniszyn L, Bartel H, Tosik D, Planeta-Malecka I. Electron microscopic study of association between coccoid forms of *Helicobacter pylori* and gastric epithelial cells. *Am J Gastroenterol* 1995; **90**: 1829-1833
- 11 Mizoguchi H, Fujioka T, Kishi K, Nishizono A, Kodama R, Nasu M. Diversity in protein synthesis and viability of *Helicobacter pylori* coccoid forms in response to various stimuli. *Infect Immun* 1998; **66**: 5555-5560
- 12 Mao HY, Fang PC, Ye SJ, You JF, Zhu YL, Yu JG. Analysis of babA2 cagA and vacA genotypes of *Helicobacter pylori* in chronic gastritis and peptic ulcer. *Zhejiang Daxue Xuebao Yixueban* 2003; **32**: 29-32
- 13 Oleastro M, Gerhard M, Lopes AI, Ramalho P, Cabral J, Sousa Guerreiro A, Monteiro L. *Helicobacter pylori* virulence genotypes in portuguese children and adults with gastroduodenal pathology. *Eur J Clin Microbiol Infect Dis* 2003; **22**: 85-91
- 14 Debets-Ossenkopp YJ, Reyes G, Mulder J, Aan De Stegge BM, Peters JT, Savelkoul PH, Tanca J, Pena AS, Vandenbroucke-Grauls CM. Characteristics of clinical *Helicobacter pylori* strains from Ecuador. *J Antimicrob Chemother* 2003; **51**: 141-145
- 15 Bravo LE, van Doorn LJ, Realpe JL, Correa P. Virulence-associated genotypes of *Helicobacter pylori*: do they explain the African enigma? *Am J Gastroenterol* 2002; **97**: 2839-2842
- 16 Kusters JG, Gerrits MM, Van Strip JA, Vandenbroucke-Grauls CM. Coccoid forms of *Helicobacter pylori* are the morphologic manifestation of cell death. *Infect Immun* 1997; **65**: 3672-3679
- 17 Narikawa S, Kawai S, Aoshima H, Kawamata O, Kawaguchi R, Hikiji K, Kato M, Iino S, Mizushima Y. Comparison of the nucleic acids of helical and coccoid forms of *Helicobacter pylori*. *Clin Diagn Lab Immunol* 1997; **4**: 285-290
- 18 Costa K, Bacher G, Allmaier G, Dominguez-Bello MG, Engstrand L, Falk P, de Pedro MA, Garcia-del Portillo F. The morphological transition of *Helicobacter pylori* cells from spiral to coccoid is preceded by a substantial modification of the cell wall. *J Bacteriol* 1999; **181**: 3710-3715
- 19 Sato F. *Helicobacter pylori* in culture: an ultrastructural study. *Hokkaido Igaku Zasshi* 2000; **75**: 187-196
- 20 Nakamura A, Park A, Nagata K, Sato EF, Kashiba M, Tamura T, Inoue M. Oxidative cellular damage associated with transformation of *Helicobacter pylori* from a bacillary to a coccoid form. *Free Radic Biol Med* 2000; **28**: 1611-1618
- 21 Monstein HJ, de la Cour CD, Jonasson J. Probing 23S ribosomal RNA cleavage sites in coccoid *Helicobacter pylori*. *Helicobacter* 2001; **6**: 100-109
- 22 Rabelo-Goncalves EM, Nishimura NF, Zeitune JM. Acute inflammatory response in the stomach of BALB/c mice challenged with coccoidal *Helicobacter pylori*. *Mem Inst Oswaldo Cruz* 2002; **97**: 1201-1206
- 23 Wang X, Sturegard E, Rupar R, Nilsson HO, Aleljung PA, Carlen B, Willen R, Wadstrom T. Infection of BALB/c A mice by spiral and coccoid forms of *Helicobacter pylori*. *J Med Microbiol* 1997; **46**: 657-663
- 24 Cao J, Li ZQ, Borch K, Petersson F, Mardh S. Detection of spiral and coccoid forms of *Helicobacter pylori* using a murine monoclonal antibody. *Clin Chim Acta* 1997; **267**: 183-196
- 25 Sisto F, Brenciaglia MI, Scaltrito MM, Dubini F. *Helicobacter pylori*: ureA, cagA and vacA expression during conversion to the coccoid form. *Int J Antimicrob Agents* 2000; **15**: 277-282
- 26 Monstein HJ, Jonasson J. Differential virulence-gene mRNA expression in coccoid forms of *Helicobacter pylori*. *Biochem Biophys Res Commun* 2001; **285**: 530-536